Name of journal: *World Journal of Clinical Oncology*

Manuscript NO: 90898

Title: Approaches and Challenges in Cancer Immunotherapy Pathways

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer’s code: 06569044

Position: Editorial Board

Academic degree: MD, PhD

Professional title: Professor

Reviewer’s Country/Territory: China

Author’s Country/Territory: Greece

Manuscript submission date: 2023-12-16

Reviewer chosen by: AI Technique

Reviewer accepted review: 2023-12-25 04:05

Reviewer performed review: 2023-12-25 08:05

Review time: 3 Hours

<table>
<thead>
<tr>
<th>Scientific quality</th>
<th>Grade A: Excellent</th>
<th>Grade B: Very good</th>
<th>Grade C: Good</th>
<th>Grade D: Fair</th>
<th>Grade E: Do not publish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Novelty of this manuscript</td>
<td>Grade A: Excellent</td>
<td>Grade B: Good</td>
<td>Grade C: Fair</td>
<td>Grade D: No novelty</td>
<td></td>
</tr>
<tr>
<td>Creativity or innovation of this manuscript</td>
<td>Grade A: Excellent</td>
<td>Grade B: Good</td>
<td>Grade C: Fair</td>
<td>Grade D: No creativity or innovation</td>
<td></td>
</tr>
</tbody>
</table>
### Scientific significance of the conclusion in this manuscript

[ ] Grade A: Excellent  [ ] Grade B: Good  [ ] Grade C: Fair  [ ] Grade D: No scientific significance

### Language quality

[ ] Grade A: Priority publishing  [ ] Grade B: Minor language polishing  [ ] Grade C: A great deal of language polishing  [ ] Grade D: Rejection

### Conclusion

[ ] Accept (High priority)  [ ] Accept (General priority)  [ ] Minor revision  [ ] Major revision  [ ] Rejection

### Re-review

[ ] Yes  [ ] No

### Peer-reviewer statements

Peer-Review: [ ] Anonymous  [ ] Onymous

Conflicts-of-Interest: [ ] Yes  [ ] No

---

**SPECIFIC COMMENTS TO AUTHORS**

The author briefly described three approaches of cancer immunotherapy, with less emphasis on the challenges faced by cancer immunotherapy. There are no particularly meaningful viewpoints or valuable concepts worth learning from. This is an editorial article. Perhaps due to word count limitations, the author did not elaborate well on the content related to the article title.
**PEER-REVIEW REPORT**

**Name of journal:** World Journal of Clinical Oncology  
**Manuscript NO:** 90898  
**Title:** Approaches and Challenges in Cancer Immunotherapy Pathways  
**Provenance and peer review:** Invited Manuscript; Externally peer reviewed  
**Peer-review model:** Single blind  
**Reviewer’s code:** 06301995  
**Position:** Peer Reviewer  
**Academic degree:** MD  
**Professional title:** Doctor  
**Reviewer’s Country/Territory:** China  
**Author’s Country/Territory:** Greece  
**Manuscript submission date:** 2023-12-16  
**Reviewer chosen by:** AI Technique  
**Reviewer accepted review:** 2023-12-26 01:40  
**Reviewer performed review:** 2023-12-26 02:05  
**Review time:** 1 Hour

<table>
<thead>
<tr>
<th>Scientific quality</th>
<th>[ ] Grade A: Excellent</th>
<th>[ ] Grade B: Very good</th>
<th>[Y] Grade C: Good</th>
<th>[ ] Grade D: Fair</th>
<th>[ ] Grade E: Do not publish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Novelty of this manuscript</td>
<td>[ ] Grade A: Excellent</td>
<td>[Y] Grade B: Good</td>
<td>[ ] Grade C: Fair</td>
<td>[ ] Grade D: No novelty</td>
<td></td>
</tr>
<tr>
<td>Creativity or innovation of</td>
<td>[ ] Grade A: Excellent</td>
<td>[ ] Grade B: Good</td>
<td>[Y] Grade C: Fair</td>
<td>[ ] Grade D: No creativity or innovation</td>
<td></td>
</tr>
<tr>
<td>Scientific significance of the conclusion in this manuscript</td>
<td>[ ] Grade A: Excellent</td>
<td>[ ] Grade B: Good</td>
<td>[ Y] Grade C: Fair</td>
<td>[ ] Grade D: No scientific significance</td>
<td></td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td></td>
</tr>
<tr>
<td>Language quality</td>
<td>[ ] Grade A: Priority publishing</td>
<td>[ Y] Grade B: Minor language polishing</td>
<td>[ ] Grade C: A great deal of language polishing</td>
<td>[ ] Grade D: Rejection</td>
<td></td>
</tr>
<tr>
<td>Conclusion</td>
<td>[ ] Accept (High priority)</td>
<td>[ Y] Accept (General priority)</td>
<td>[ ] Minor revision</td>
<td>[ ] Major revision</td>
<td>[ ] Rejection</td>
</tr>
<tr>
<td>Re-review</td>
<td>[ Y] Yes</td>
<td>[ ] No</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Peer-reviewer statements</td>
<td>Peer-Review: [ Y] Anonymous</td>
<td>[ ] Onymous</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Conflicts-of-Interest:</td>
<td>[ ] Yes</td>
<td>[ Y] No</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**SPECIFIC COMMENTS TO AUTHORS**

The immunotherapy of tumor is a hot topic at present, and the conclusion stated by the author is more fair. Although this therapy is not a panacea, it still has great research prospects. There is no problem in the content of the paper, and various problems in clinical use are summarized. From a clinical point of view, the paper is worth publishing...
Name of journal: *World Journal of Clinical Oncology*

Manuscript NO: 90898

Title: Approaches and Challenges in Cancer Immunotherapy Pathways

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer’s code: 07681391

Position: Peer Reviewer

Academic degree: PhD

Professional title: Professor

Reviewer’s Country/Territory: China

Author’s Country/Territory: Greece

Manuscript submission date: 2023-12-16

Reviewer chosen by: AI Technique

Reviewer accepted review: 2023-12-24 05:30

Reviewer performed review: 2024-01-02 02:07

Review time: 8 Days and 20 Hours

<table>
<thead>
<tr>
<th>Scientific quality</th>
<th>Grade A: Excellent</th>
<th>Grade B: Very good</th>
<th>Grade C: Good</th>
<th>Grade D: Fair</th>
<th>Grade E: Do not publish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Novelty of this manuscript</td>
<td>Grade A: Excellent</td>
<td>Grade B: Good</td>
<td>Grade C: Fair</td>
<td>Grade D: No novelty</td>
<td></td>
</tr>
<tr>
<td>Creativity or innovation of this manuscript</td>
<td>Grade A: Excellent</td>
<td>Grade B: Good</td>
<td>Grade C: Fair</td>
<td>Grade D: No creativity or innovation</td>
<td></td>
</tr>
<tr>
<td>Scientific significance of the conclusion in this manuscript</td>
<td>[ ] Grade A: Excellent [ ] Grade B: Good [Y] Grade C: Fair [ ] Grade D: No scientific significance</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Language quality</td>
<td>[ ] Grade A: Priority publishing [Y] Grade B: Minor language polishing [ ] Grade C: A great deal of language polishing [ ] Grade D: Rejection</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Conclusion</td>
<td>[ ] Accept (High priority) [ ] Accept (General priority) [Y] Minor revision [ ] Major revision [ ] Rejection</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Re-review</td>
<td>[Y] Yes [ ] No</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Peer-reviewer statements</td>
<td>Peer-Review: [Y] Anonymous [ ] Onymous</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Conflicts-of-Interest: [ ] Yes [Y] No</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**SPECIFIC COMMENTS TO AUTHORS**

1. “Tumor mutation burden (TMB) plays a vital role within efficient tumor immunity targets, inhibiting their growth and hence therapeutic regression. ” This sentence has a grammatical error.

2. “Experimental neogenic vaccines focused primarily on pinpointing TMJ could expand field discoveries, significantly improving patient outcome prospects, and ultimately, born-out research progression.” What is the meaning of TMJ in this sentence. Should be TMB?

3. Could the author more specifically summarizes the approaches and challenges in targeting TMB.
RE-REVIEW REPORT OF REVISED MANUSCRIPT

Name of journal: World Journal of Clinical Oncology

Manuscript NO: 90898

Title: Approaches and Challenges in Cancer Immunotherapy Pathways

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer’s code: 06569044
Position: Editorial Board
Academic degree: MD, PhD
Professional title: Professor
Reviewer’s Country/Territory: China
Author’s Country/Territory: Greece
Manuscript submission date: 2023-12-16
Reviewer chosen by: Ze-Mao Gong
Reviewer accepted review: 2024-02-06 03:48
Reviewer performed review: 2024-02-06 04:31
Review time: 1 Hour

<table>
<thead>
<tr>
<th>Scientific quality</th>
<th>[ ] Grade A: Excellent</th>
<th>[ ] Grade B: Very good</th>
<th>[Y] Grade C: Good</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>[ ] Grade D: Fair</td>
<td>[ ] Grade E: Do not publish</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Language quality</th>
<th>[Y] Grade A: Priority publishing</th>
<th>[ ] Grade B: Minor language polishing</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>[ ] Grade C: A great deal of language polishing</td>
<td>[ ] Grade D: Rejection</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Conclusion</th>
<th>[ ] Accept (High priority)</th>
<th>[Y] Accept (General priority)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>[ ] Minor revision</td>
<td>[ ] Major revision</td>
</tr>
<tr>
<td></td>
<td>[ ] Rejection</td>
<td>[Y] No</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Peer-review statements</th>
<th>Peer-Review: [Y] Anonymous</th>
<th>[ ] Onymous</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Conflicts-of-Interest: [ ] Yes</td>
<td>[Y] No</td>
</tr>
</tbody>
</table>
SPECIFIC COMMENTS TO AUTHORS
The author summarizes the approaches and challenges in immunotherapy in the revised manuscript.